Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway

Oncotarget

Volumn 5, Issue 9, 2014, Pages 2404-2417

  Rahmutulla, Bahityar ^a,c   Matsushita, Kazuyuki ^a,b   Satoh, Mamoru ^a,b   Seimiya, Masanori ^a,b   Tsuchida, Sachio ^a   Kubo, Shuji ^d   Shimada, Hideaki ^e   Ohtsuka, Masayuki ^a   Miyazaki, Masaru ^a   Nomura, Fumio ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c Department of Orthopedics and Traumatology Hospital of Uyghur Medicine   (China)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

Bleomycin(BLM); C Myc; DNA damage; FBP interacting repressor (FIR); Ku86; P27Kip1

Indexed keywords

BINDING PROTEIN; BLEOMYCIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; DNA; HETERODIMER; HOMODIMER; RNA; SMALL INTERFERING RNA; XRCC1 PROTEIN; ANTINEOPLASTIC ANTIBIOTIC; DNA HELICASE; MESSENGER RNA; MYC PROTEIN; POLY-U BINDING SPLICING FACTOR 60KDA; REPRESSOR PROTEIN; RNA BINDING PROTEIN; XRCC5 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL FATE; COLORECTAL CANCER; DNA DAMAGE; DNA STRAND BREAKAGE; EXON; HEPATOBLASTOMA; HUMAN; IMMUNOPRECIPITATION; MOLECULAR SENSOR; ONCOGENE C MYC; PROTEIN EXPRESSION; REPRESSOR GENE; ANIMAL; ANIMAL EMBRYO; ANTAGONISTS AND INHIBITORS; APOPTOSIS; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; ENZYME IMMUNOASSAY; FIBROBLAST; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; GENETICS; KNOCKOUT MOUSE; LIVER TUMOR; METABOLISM; MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ALTERNATIVE SPLICING; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLEOMYCIN; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA DAMAGE; DNA HELICASES; EMBRYO, MAMMALIAN; FIBROBLASTS; FLOW CYTOMETRY; HEPATOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84901217740     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1650     Document Type: Article

References (47)

1. Avigan MI, Strober B, Levens D. A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J Biol Chem. 1990; 265: 18538-45.
2. Duncan R, Bazar L, Michelotti G, Tomonaga T, Krutzsch H, Avigan M, Levens D. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev. 1994; 8: 465-80.
3. Bazar L, Meighen D, Harris V, Duncan R, Levens D, Avigan M. Targeted melting and binding of a DNA regulatory element by a transactivator of c-myc. J Biol Chem. 1995; 270: 8241-8.
4. Liu J, He L, Collins I, Ge H, Libutti D, Li J, Egly JM, Levens D. The FBP interacting repressor targets TFIIH to inhibit activated transcription. Mol Cell. 2000; 5: 331-41.
5. Liu J, Akoulitchev S, Weber A, Ge H, Chuikov S, Libutti D, Wang XW, Conaway JW, Harris CC, Conaway RC, Reinberg D, Levens D. Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum. Cell. 2001; 104: 353-63.
6. Liu J, Kouzine F, Nie Z, Chung HJ, Elisha-Feil Z, Weber A, Zhao K, Levens D. The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression. EMBO J. 2006; 25(10): 2119-30.
7. Kouzine F, Gupta A, Baranello L, Wojtowicz D, Ben-Aissa K, Liu J, Przytycka TM, Levens D. Transcription-dependent dynamic supercoiling is a short-range genomic force. Nat Struct Mol Biol. 2013; 20(3): 396-403.
8. Kouzine F, Wojtowicz D, Yamane A, Resch W, Kieffer-Kwon KR, Bandle R, Nelson S, Nakahashi H, Awasthi P, Feigenbaum L, Menoni H, Hoeijmakers J, Vermeulen W, Ge H, Przytycka TM, Levens D et al. Global regulation of promoter melting in naive lymphocytes. Cell. 2013; 153(5): 988-99.
9. Matsushita K, Tomonaga T, Shimada H, Shioya A, Higashi M, Matsubara H, Harigaya K, Nomura F, Libutti D, Levens D, Ochiai T. An essential role of alternative splicing of c-myc suppressor FIR in carcinogenesis. Cancer Res. 2006; 66: 1409-17.
10. Will CL, Urlaub H, Achsel T, Gentzel M, Wilm M, Luhrmann R. Characterization of novel SF3b and 17S U2 snRNP proteins, including a human Prp5p homologue and an SF3b DEAD-box protein. EMBO J. 2002; 21: 4978-88.
11. Matsushita K, Kajiwara T, Tamura M, Satoh M, Tanaka N, Tomonaga T, Matsubara H, Shimada H, Yoshimoto R, Ito A, Kubo S, Natsume T, Levens D, Yoshida M, Nomura F. SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression. Mol Cancer Res. 2012; 10: 787-99.
12. Matsushita K, Kobayashi S, Kato M, Itoh Y, Okuyama K, Sakiyama S, Isono K. Reduced messenger RNA expression level of p21 CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation. Int J Cancer. 1996; 69: 259-64.
13. Starostina NG, Kipreos ET. Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors. Trends Cell Biol. 2012; 22: 33-41.
14. Matsushita K, Tamura M, Tanaka N, Tomonaga T, Matsubara H, Shimada H, Levens D, He L, Liu J, Yoshida M, Nomura F. Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-myc and P27Kip1 expression. Mol Cancer Res. 2013; 11(7): 689-98.
15. Zhang J, Chen QM. Far upstream element binding protein 1: a commander of transcription, translation and beyond. Oncogene. 2012; e-pub ahead of print 27 Aug 2012; doi:10.1038/onc. 2012.350.
16. Dong F, Soubeyrand S, Haché RJ. Activation of PARP-1 in response to bleomycin depends on the Ku antigen and protein phosphatase 5. Oncogene. 2010; 29(14): 2093-103.
17. Povirk LF. DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Mutat Res. 1996; 355(1-2): 71-89.
18. Benítez-Bribiesca L, Sánchez-Suárez P. Oxidative damage, bleomycin, and gamma radiation induce different types of DNA strand breaks in normal lymphocytes and thymocytes. A comet assay study. Ann N Y Acad Sci. 1999; 887: 133-49.
19. De Vita V.T., S. Hellman, S.A. Rosenberg. Cancer Principles and Practice of Oncology. Lippincott-Raven Pub. Philadelphia-New York. 1997; pp. 495-497.
20. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001; 411(6835): 366-74.
21. Collis SJ, DeWeese TL, Jeggo PA, Parker AR. The life and death of DNA-PK. Oncogene. 2005; 24(6): 949-61.
22. Metcalf JL, Bradshaw PS, Komosa M, Greer SN, Stephen Meyn M, Ohh M. K63-Ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair. Oncogene. 2013; e-pub ahead of print 4 Mar 2013; doi: 10.1038/onc. 2013.22.
23. Vilenchik MM, Knudson AG. Endogenous DNA double-strand breaks: Production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci U S A. 2003; 100(22): 12871-6.
24. Grob P, Zhang TT, Hannah R, Yang H, Hefferin ML, Tomkinson AE, Nogales E. Electron microscopy visualization of DNA-protein complexes formed by Ku and DNA ligase IV. DNA Repair. (Amst) 2012; 11(1): 74-81.
25. Kajiwara T, Matsushita K, Itoga S, Tamura M, Tanaka N, Tomonaga T, Matsubara H, Shimada H, Habara Y, Matsuo M, Nomura F. SAP155-mediated c-myc suppressor far-upstream element-binding protein-interacting repressor splicing variants are activated in colon cancer tissues. Cancer Sci. 2013; 104(2): 149-56.
26. Spagnolo L, Barbeau J, Curtin NJ, Morris EP, Pearl LH. Visualization of a DNA-PK/PARP1 complex. Nucleic Acids Res. 2012; 40(9): 4168-77.
27. Seimiya M, Tomonaga T, Matsushita K, Sunaga M, Oh-Ishi M, Kodera Y, Maeda T, Takano S, Togawa A, Yoshitomi H, Otsuka M, Yamamoto M, Nakano M, Miyazaki M, Nomura F. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology. 2008; 48(2): 519-30.
28. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, Watanabe H, Kitahara T, Yoshida T, Nakajima H, Tani T, Horinouchi S, Yoshida M. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol. 2007; 3: 576-83.
29. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998; 396(6712): 643-9.
30. Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IP, Howell M, Kschischo M, Swanton C. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 2011; 71(5): 1858-70.
31. Woodford-Richens KL, Rowan AJ, Gorman P, Halford S, Bicknell DC, Wasan HS, Roylance RR, Bodmer WF, Tomlinson IP. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc Natl Acad Sci USA. 2001; 98(17): 9719-23.
32. Gaasenbeek M, Howarth K, Rowan AJ, Gorman PA, Jones A, Chaplin T, Liu Y, Bicknell D, Davison EJ, Fiegler H, Carter NP, Roylance RR, Tomlinson IP. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers. Cancer Res. 2006; 66(7): 3471-9.
33. Abdel-Rahman WM, Katsura K, Rens W, Gorman PA, Sheer D, Bicknell D, Bodmer WF, Arends MJ, Wyllie AH, Edwards PA. Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proc Natl Acad Sci USA. 2001; 98(5): 2538-43.
34. Gille JJ, Joenje H. Chromosomal instability and progressive loss of chromosomes in HeLa cells during adaptation to hyperoxic growth conditions. Mutat Res. 1989; 219(4): 225-30.
35. Kristjansdottir K, Wolfgeher D, Lucius N, Angulo DS, Kron SJ. Phosphoprotein profiling by PA-GeLC-MS/MS. J Proteome Res. 2008; 7: 2812-24.
36. Wang Z, Inuzuka H, Zhong J, Wan L, Fukushima H, Sarkar FH, Wei W. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 2012; 586(10): 1409-18.
37. Li R, Yang Y, An Y, Zhou Y, Liu Y, Yu Q, Lu D, Wang H, Jin L, Zhou W, Qian J, Shugart YY. Genetic polymorphism in DNA double-strand break repair genes XRCC5, XRCC6 and susceptibility to hepatocellular carcinoma. Carcinogenesis. 2011; 32(4): 530-6.
38. Nomura F, Sogawa K, Noda K, Seimiya M, Matsushita K, Miura T, Tomonaga T, Yoshitomi H, Imazeki F, Takizawa H, Mogushi K, Miyazaki M, Yokosuka O. Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma. Biochem Biophys Res Commun. 2012; 421(4): 837-43.
39. Wei S, Xiong M, Zhan DQ, Liang BY, Wang YY, Gutmann DH, Huang ZY, Chen XP. Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway. Carcinogenesis. 2012; 33(3): 538-47.
40. Idogawa M, Masutani M, Shitashige M, Honda K, Tokino T, Shinomura Y, Imai K, Hirohashi S, Yamada T. Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate beta-catenin and T-cell factor-4-mediated gene transactivation: possible linkage of DNA damage recognition and Wnt signaling. Cancer Res. 2007; 67(3): 911-8.
41. Lentini L, Amato A, Schillaci T, Di Leonardo A. Simultaneous Aurora-A/STK15 overexpression and centrosome amplification induce chromosomal instability in tumour cells with a MIN phenotype. BMC Cancer. 2007; 7:212.
42. Seghezzi W, Chua K, Shanahan F, Gozani O, Reed R, Lees E. Cyclin E associates with components of the pre-mRNA splicing machinery in mammalian cells. Mol Cell Biol. 1998; 18(8): 4526-36.
43. Habara Y, Urushiyama S, Tani T, Ohshima Y. The fission yeast prp10(+) gene involved in pre-mRNA splicing encodes a homologue of highly conserved splicing factor, SAP155. Nucleic Acids Res. 1998; 26(24): 5662-9.
44. Habara Y, Urushiyama S, Shibuya T, Ohshima Y, Tani T. Mutation in the prp12+ gene encoding a homolog of SAP130/SF3b130 causes differential inhibition of pre-mRNA splicing and arrest of cell-cycle progression in Schizosaccharomyces pombe. RNA. 2001; 7(5): 671-81.
45. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008; 10: e19.
46. Matsushita K, Tomonaga T, Kajiwara T, Shimada H, Itoga S, Hiwasa T, Kubo S, Ochiai T, Matsubara H, Nomura F. c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy. Front Biosci. 2009; 14: 3401-8.
47. Kimura K, Nozaki N, Enomoto T, Tanaka M, Kikuchi A. Analysis of M phase-specific phosphorylation of DNA topoisomerase II. J Biol Chem. 1996; 271: 21439-45.